The CORT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CORT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CORT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CORT Detailed Price Forecast - CNN Money||View CORT Detailed Summary - Google Finance|
|View CORT Detailed Summary - Yahoo! Finance||View CORT Stock Research & Analysis - Zacks.com|
|View CORT Trends & Analysis - Trade-Ideas||View CORT Major Holders - Barrons|
|View CORT Call Transcripts - NASDAQ||View CORT Breaking News & Analysis - Seeking Alpha|
|View CORT Annual Report - CompanySpotlight.com||View CORT OTC Short Report - OTCShortReport.com|
|View CORT Fundamentals - TradeKing||View CORT SEC Filings - Bar Chart|
|View Historical Prices for CORT - The WSJ||View Performance/Total Return for CORT - Morningstar|
|View the Analyst Estimates for CORT - MarketWatch||View the Earnings History for CORT - CNBC|
|View the CORT Earnings - StockMarketWatch||View CORT Buy or Sell Recommendations - MacroAxis|
|View the CORT Bullish Patterns - American Bulls||View CORT Short Pain Metrics - ShortPainBot.com|
|View CORT Stock Mentions - StockTwits||View CORT Stock Mentions - PennyStockTweets|
|View CORT Stock Mentions - Twitter||View CORT Investment Forum News - Investor Hub|
|View CORT Stock Mentions - Yahoo! Message Board||View CORT Stock Mentions - Seeking Alpha|
|View Insider Transactions for CORT - SECform4.com||View Insider Transactions for CORT - Insider Cow|
|View CORT Major Holdings Summary - CNBC||View Insider Disclosure for CORT - OTC Markets|
|View Insider Transactions for CORT - Yahoo! Finance||View Institutional Holdings for CORT - NASDAQ|
|View CORT Stock Insight & Charts - FinViz.com||View CORT Investment Charts - StockCharts.com|
|View CORT Stock Overview & Charts - BarChart||View CORT User Generated Charts - Trading View|
Corcept Therapeutics Incorporated (NASDAQ:CORT) Has Attractive Fundamentals, Here’s Why
Posted on Tuesday June 19, 2018
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
Today's Research Reports on Trending Tickers: Corcept Therapeutics and CRISPR Therapeutics
Posted on Tuesday June 19, 2018
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / U.S. markets finished mostly lower on Monday, with the Dow logging its 5th straight decline, on fears of growing trade tensions between the U.S. and China. The ...
Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?
Posted on Thursday June 07, 2018
Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting
Posted on Monday June 04, 2018
Corcept Therapeutics Incorporated (CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced that it is presenting preliminary data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) to treat patients with solid tumors. The data will be exhibited today in a poster at the 2018 American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois (June 1 – 5). “Data from the initial, dose-finding portion of this trial are striking,” said Robert S. Fishman, MD, Corcept’s Chief Medical Officer.